Master protocols could allow pediatric cancer trials to become a more proactive and efficient drug development exercise rather than the regulatory-driven, reactive approach that has long guided investigation of new oncologic agents for use in children and adolescents.
However, the ability to accomplish this task may depend upon a number of factors, including the willingness of sponsors to...





